BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 15180491)

  • 1. Cytochrome P450 gene polymorphism and cancer.
    Agundez JA
    Curr Drug Metab; 2004 Jun; 5(3):211-24. PubMed ID: 15180491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells.
    Wu Y; Chitranshi P; Loukotková L; Gamboa da Costa G; Beland FA; Zhang J; Fang JL
    Arch Toxicol; 2017 Jun; 91(6):2405-2423. PubMed ID: 27896399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers.
    He X; Feng S
    Curr Drug Metab; 2015; 16(10):850-63. PubMed ID: 26652254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk.
    Bozina N; Bradamante V; Lovrić M
    Arh Hig Rada Toksikol; 2009 Jun; 60(2):217-42. PubMed ID: 19581216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases.
    Daly AK
    Adv Pharmacol; 2015; 74():85-111. PubMed ID: 26233904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.
    Chamboko CR; Veldman W; Tata RB; Schoeberl B; Tastan Bishop Ö
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase.
    Fujita K; Kamataki T
    Mutat Res; 2001 Nov; 483(1-2):35-41. PubMed ID: 11600130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma.
    Zhou J; Wen Q; Li SF; Zhang YF; Gao N; Tian X; Fang Y; Gao J; Cui MZ; He XP; Jia LJ; Jin H; Qiao HL
    Oncotarget; 2016 Aug; 7(31):50612-50623. PubMed ID: 27203676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase.
    Fujita K; Kamataki T
    Environ Mol Mutagen; 2001; 38(4):339-46. PubMed ID: 11774366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms of human N-acetyltransferases and cancer risk.
    Agúndez JA
    Curr Drug Metab; 2008 Jul; 9(6):520-31. PubMed ID: 18680472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
    Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
    Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer.
    Silvestri L; Sonzogni L; De Silvestri A; Gritti C; Foti L; Zavaglia C; Leveri M; Cividini A; Mondelli MU; Civardi E; Silini EM
    Int J Cancer; 2003 Apr; 104(3):310-7. PubMed ID: 12569554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis.
    Elfaki I; Mir R; Almutairi FM; Duhier FMA
    Asian Pac J Cancer Prev; 2018 Aug; 19(8):2057-2070. PubMed ID: 30139042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between non-occupational cadmium exposure and expression of nine cytochrome P450 forms in human liver and kidney cortex samples.
    Baker JR; Satarug S; Reilly PE; Edwards RJ; Ariyoshi N; Kamataki T; Moore MR; Williams DJ
    Biochem Pharmacol; 2001 Sep; 62(6):713-21. PubMed ID: 11551516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1.
    Roos PH; Bolt HM
    Expert Opin Drug Metab Toxicol; 2005 Aug; 1(2):187-202. PubMed ID: 16922636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450 in Pharmacogenetics: An Update.
    Tornio A; Backman JT
    Adv Pharmacol; 2018; 83():3-32. PubMed ID: 29801580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro assessment of the allelic variants of cytochrome P450.
    Hiratsuka M
    Drug Metab Pharmacokinet; 2012; 27(1):68-84. PubMed ID: 22041138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts.
    Ding X; Kaminsky LS
    Annu Rev Pharmacol Toxicol; 2003; 43():149-73. PubMed ID: 12171978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
    Fujita K; Nakayama K; Yamazaki Y; Tsuruma K; Yamada M; Nohmi T; Kamataki T
    Environ Mol Mutagen; 2001; 38(4):329-38. PubMed ID: 11774365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
    Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
    Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.